Piper Sandler initiates Tenax Therapeutics stock with Overweight rating

Piper Sandler initiated coverage on Tenax Therapeutics (TENX) with an Overweight rating and a $20.00 price target, highlighting the potential of its oral levosimendan treatment, TNX-103, for a large pulmonary hypertension market, with Phase 3 LEVEL trial results expected as a key catalyst in H2 2026. This positive outlook follows a recent delay in the LEVEL trial timeline, which prompted Guggenheim to slightly adjust its price target from $15.00 to $14.00, while maintaining its Buy rating, reflecting a nuanced but overall confident view on the company's prospects.

Analysis

Piper Sandler has initiated coverage on Tenax Therapeutics (TENX) with a notably bullish outlook, assigning an Overweight rating and a $20.00 price target, which represents a significant premium to its current $6.00 trading price. The firm's confidence is anchored in the potential of TNX-103, an oral levosimendan treatment for pulmonary hypertension with heart failure (PH-HFpEF), a condition projected to affect 2.2-3.7 million U.S. patients by 2030. Piper Sandler considers the drug's prospects to be substantially de-risked due to strong Phase 2 data. However, this optimism is tempered by operational realities, as Tenax recently announced a delay in its Phase 3 LEVEL trial, pushing the expected completion of patient enrollment to the first half of 2026. This delay prompted Guggenheim to revise its price target downward from $15.00 to $14.00, though it maintained its Buy rating, suggesting continued conviction in the long-term thesis despite short-term execution setbacks. The primary value-driving catalyst for TENX remains the Phase 3 trial results, now anticipated in the second half of 2026, positioning the stock as a long-dated, binary play on a single clinical asset.

Key Decisions for Investors

• Given the stock's value is overwhelmingly tied to the success of a single drug, TNX-103, investors should treat TENX as a high-risk, high-reward speculative holding suitable for a well-diversified portfolio.
• The key inflection point is the Phase 3 LEVEL trial data readout in H2 2026; therefore, this is a long-term investment where any further adjustments to the clinical trial timeline will be a primary source of stock volatility and must be monitored closely.
• While analyst price targets from Piper Sandler ($20) and Guggenheim ($14) suggest substantial upside, the recent trial delay underscores execution risk, making it prudent to consider the long and uncertain path to regulatory approval before committing significant capital.